David Hoang Analyst Performance

Analyst at Deutsche Bank Aktiengesellschaft

David Hoang is a stock analyst at Deutsche Bank Aktiengesellschaft in the medical sector, covering 11 publicly traded companies. Over the past year, David Hoang has issued 15 stock ratings, including buy, hold, and sell recommendations. While full access to David Hoang's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Hoang's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 15 Last 0 Years
Buy Recommendations: 80.00% 12 Buy Ratings
Companies Covered: 11 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	80.0%	12 ratings
Hold	13.3%	2 ratings
Sell	6.7%	1 ratings

Out of 15 total stock ratings issued by David Hoang at Deutsche Bank Aktiengesellschaft, the majority (80.0%) have been Buy recommendations, followed by 13.3% Hold and 6.7% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	90.9% of companies on NASDAQ	10 companies
NYSE	9.1% of companies on NYSE	1 company

David Hoang, an analyst at Deutsche Bank Aktiengesellschaft, currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 11 companies	100.0%

David Hoang of Deutsche Bank Aktiengesellschaft specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 10 companies	90.9%
MED - DRUGS 1 company	9.1%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SRPT Sarepta Therapeutics	8/15/2025	Boost Price Target	$21.76	$12.00	Sell
JAZZ Jazz Pharmaceuticals	7/15/2025	Initiated Coverage	$111.44	$152.00	Buy
HRMY Harmony Biosciences	7/10/2025	Reiterated Rating	$34.35	$55.00	Buy
SRPT Sarepta Therapeutics	6/17/2025	Lower Price Target	$21.94	$25.00	Hold
ACAD ACADIA Pharmaceuticals	5/21/2025	Upgrade	$21.69	$35.00	Buy
ALKS Alkermes	3/27/2025	Boost Price Target	$33.69	$52.00	Buy
SRPT Sarepta Therapeutics	3/19/2025	Lower Price Target	$73.54	$99.00	Hold
PRAX Praxis Precision Medicines	2/11/2025	Initiated Coverage	$84.85	$111.00	Buy
XENE Xenon Pharmaceuticals	2/11/2025	Initiated Coverage	$39.25	$67.00	Buy
ALKS Alkermes	2/11/2025	Initiated Coverage	$31.23	$40.00	Buy
AVDL Avadel Pharmaceuticals	2/11/2025	Initiated Coverage	$9.09	$12.00	Buy
AXSM Axsome Therapeutics	2/11/2025	Initiated Coverage	$127.08	$176.00	Buy
BHVN Biohaven	2/11/2025	Initiated Coverage	$38.25	$65.00	Buy
DNLI Denali Therapeutics	2/11/2025	Initiated Coverage	$20.88	$31.00	Buy
HRMY Harmony Biosciences	2/11/2025	Initiated Coverage	$37.99	$55.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.